A study to be presented at the American Diabetes Association's 79th Scientific Sessions showed that linagliptin was noninferior in terms of time to first occurrence of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death over an average of six years, compared with glimepiride. Researchers evaluated data from the CAROLINA study involving 6,033 type 2 diabetes patients at high CV risk or established CV disease who received 5 mg linagliptin once daily and found that linagliptin's overall safety profile in the study was consistent with previous findings.
Research shows safety of linagliptin in diabetes, CV patients
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.